Toronto Dominion Bank Invests $984,000 in United Therapeutics Co. (NASDAQ:UTHR)

Toronto Dominion Bank purchased a new position in United Therapeutics Co. (NASDAQ:UTHR – Get Rating) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 4,700 shares of the biotechnology company’s stock, valued at approximately $984,000.

Other institutional investors also recently made changes to their positions in the company. Cullen Frost Bankers Inc. acquired a new position in shares of United Therapeutics in the second quarter worth $26,000. Hallmark Capital Management Inc. acquired a new position in United Therapeutics in the second quarter valued at $33,000. Ronald Blue Trust Inc. acquired a new position in United Therapeutics in the second quarter valued at $28,000. Neo Ivy Capital Management acquired a new position in United Therapeutics in the second quarter valued at $48,000. Finally, Quadrant Capital Group LLC increased its stake in United Therapeutics by 51.0% in the second quarter. Quadrant Capital Group LLC now owns 225 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 76 shares during the last quarter. 95.63% of the stock is owned by institutional investors and hedge funds.

Get United Therapeutics alerts:

Insider Activity at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 6,000 shares of the company’s stock in a transaction dated Thursday, December 1st. The shares were sold at an average price of $277.65, for a total value of $1,665,900.00. Following the completion of the transaction, the executive vice president now directly owns 36,397 shares of the company’s stock, valued at approximately $10,105,627.05. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, EVP Paul A. Mahon sold 6,000 shares of United Therapeutics stock in a transaction dated Thursday, December 1st. The stock was sold at an average price of $277.65, for a total transaction of $1,665,900.00. Following the sale, the executive vice president now directly owns 36,397 shares of the company’s stock, valued at $10,105,627.05. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Paul A. Mahon sold 12,000 shares of United Therapeutics stock in a transaction dated Thursday, December 15th. The stock was sold at an average price of $196.31, for a total value of $2,355,720.00. Following the sale, the executive vice president now directly owns 36,397 shares in the company, valued at $7,145,095.07. The disclosure for this sale can be found here. In the last three months, insiders sold 223,420 shares of company stock valued at $58,953,729. Corporate insiders own 12.40% of the company’s stock.

Analyst Ratings Changes

UTHR has been the subject of several analyst reports. Oppenheimer upped their target price on United Therapeutics from $325.00 to $375.00 and gave the company an “outperform” rating in a research note on Thursday, November 3rd. HC Wainwright boosted their price objective on shares of United Therapeutics from $255.00 to $300.00 and gave the company a “buy” rating in a research note on Thursday, November 3rd. Morgan Stanley upped their price objective on United Therapeutics from $322.00 to $330.00 and gave the stock an “overweight” rating in a report on Tuesday, December 6th. JPMorgan Chase & Co. boosted their price target on United Therapeutics from $240.00 to $265.00 and gave the company an “overweight” rating in a research report on Thursday, November 3rd. Finally, StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, November 3rd. Two equities research analysts have rated the stock with a sell rating, nine have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $283.64.

United Therapeutics Trading Down 1.1 %

UTHR opened at $253.14 on Wednesday. The firm’s 50 day moving average is $267.16 and its 200-day moving average is $244.13. United Therapeutics Co. has a 52-week low of $158.38 and a 52-week high of $283.09. The company has a quick ratio of 9.39, a current ratio of 9.68 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $11.54 billion, a P/E ratio of 17.22, a P/E/G ratio of 1.81 and a beta of 0.63.

United Therapeutics Profile

(Get Rating)

United Therapeutics Corp. operates as a biotechnology company engaged in the development and commercialization of products for patients with chronic and life-threatening diseases. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. It is involved in the development of novel pharmaceutical therapies and technologies that expand the availability of transplantable organs.

Featured Articles

• Get a free copy of the StockNews.com research report on United Therapeutics (UTHR)
• LCI Industries Diversification Strategy Pays Off
• Is It Time To Buy The Dip In The Coca-Cola Company 
• Ex-Dividend Date vs. Record Date: What’s the Difference?
• How Does the Consumer Price Index Affect the Stock Market?
• Are Denny’s Corporation Investors Due For A Grand Slam?

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR – Get Rating).

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.